If it wins the federal OK, the company hopes to debut the late-stage drug candidate on the market within the next two years.
{iframe}https://www.bizjournals.com/washington/news/2017/09/18/md-biotech-expands-hq-in-ramp-up-for-potential.html{/iframe}
Sucampo Pharmaceuticals expands HQ, ramps up for potential FDA drug approval – Washington Business Journal